EMG
MLNT

Ellington Management Group’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Ellington Management Group’s Portfolio MLNT Stock Details MLNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-5,460
Closed -$173K – 768
2018
Q2 		$173K Buy
+5,460
New +$197K 0.01% 435

Other funds holding MLNT

OH
Oikos Holdings New York $422M AUM 13.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ellington Management Group's MLNT Position: Q3 2018 in Review

Ellington Management Group sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q3 2018, closing a stake of 5,460 shares — an estimated $173K sold.

Ellington Management Group first reported a position in MLNT in Q2 2018 and held it in 1 quarter. The position peaked at $173K in Q2 2018. 91 funds tracked by Wall St. Rank hold MLNT as of Q3 2018.

  • Ellington Management Group reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Ellington Management Group sold 5,460 Melinta Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $173K.
  • Ellington Management Group first reported a position in Melinta Therapeutics, Inc. Common Stock in Q2 2018 and held it in 1 quarter.
  • Ellington Management Group's Melinta Therapeutics, Inc. Common Stock position peaked at $173K in Q2 2018.
  • 91 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Ellington Management Group's 13F filing for Q3 2018, filed 14 Nov 2018.